• Computational Chemists
  The generation of novel compounds with corresponding biological data provides the basis for more sophisticated and robust molecular modeling and/or docking studies, SAR and even QSAR analysis.
  
  
• Medicinal Chemists
  EMD provides novel biological relevant lead scaffolds that, typically, are not intuitively obvious. Subsequent modifications will generate optimized leads with the required biological activity, appropriate physical properties and ADME/Tox profiles.
  
  
• Combinatorial Chemists
  EMD provides novel scaffolds for the design/generation of focused combinatorial libraries with relevant pharmacological activity resulting in a greater hit-ratio.
  
  
• Pharmacologists
  A multitude of novel, diverse compounds with designed affinity, selectivity and specificity for a given biological target which reduces the risk of failure and significantly increases the chances of obtaining successful IND candidates.
  

• Molecular Biologists
  Together with our expertise in computational and medicinal chemistry as well as pharmacology, the EMD process rapidly advances "DNA-to-Drug" programs.   Proprietary validated drug targets derived from genomics and proteomics are thereby exploited to their full potential.
  
  
• IT Specialists
  Technical integration into existing hardware and software is not required: we can work with all standard file-formats.
  
  
• IP Managers
  A diverse and large number of novel chemical structures/compounds with specified biological activities enables a broad patent protection portfolio for a given (proprietary) biological target.